The device uses neutrophil movement and its correlation with infection to detect sepsis. A commercial version could be several years away, however.
The researchers said that their deep-learning interpreter of outcomes for patients with gliomas could be more accurate and objective than pathologists.
Because of a statistical error in a recent study, the firm reduced test performance numbers, but it noted that the revised numbers are still far better than standard histopathology.
They have begun clinical testing of a table-top centrifuge and microfluidic chip that efficiently separated exosomes and enabled testing for disease markers in an internal study.
The researchers said that their reagent, which makes TB cells emit light, could be integrated into slide-and-microscope testing platforms.
The researchers said that a study to validate their concept showed that the platform has potential to detect cancer and infectious disease biomarkers in human blood.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
The device is an electrochemical lateral flow immunosensor test that will initially be used to detect dengue hemorrhagic fever, and later, to assess stroke severity.
A broad team of researchers has developed a microarray that looks for 171,000 different peptide fragments to differentiate among tick-borne diseases.
The test would also be used to detect antibiotic susceptibility. Fraunhofer received £900,000 from SBRI Healthcare in support of the project to develop the test.